Skip to navigation

MET

MET is one of the most frequently abnormally activated kinases in several human cancers. MET activating mutations and gene amplifications have been identified as drivers of tumor growth and progression in multiple types of cancer, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). MET is also implicated as a key factor in resistance to EGFR and VEGFR therapies.

Clinical Trials Targeting MET

Indications: Non-Small Cell Lung Cancer with Gastric/Gastroesophageal
 
Drug Candidate: MGCD265
 
Driver Mutations: MET, Axl

A Phase 1 study evaluating the effects of MGCD265 as a treatment for non-small cell lung cancer whose tumors carry genetic alterations of MET and Axl. Participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if those genetic alterations are present before patients enroll in the clinical trial.



Indications: Head and Neck Squamous Cell Carcinoma with Gastric/Gastroesophageal
 
Drug Candidate: MGCD265
 
Driver Mutations: MET, Axl

A Phase 1 study evaluating the effects of MGCD265 as a treatment for head and neck cancer whose tumors carry genetic alterations of MET and Axl. Participating trial sites will analyze the genetic sequence of the tumors of eligible patients to determine if those mutations are present before enrolling in the clinical trial.

Find an Active Trial